Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells.

Chronic lymphocytic leukemia (CLL) is an indolent malignancy of CD5+ B lymphocytes. CLL cells express CD40, a key regulator of B cell proliferation, differentiation, and survival. In nonmalignant B cells, CD40 ligation results in nuclear translocation and activation of NF-kappaB proteins. Based on observations that in some CLL cases, the tumor cells express both CD40 and its ligand, CD154 (CD40 ligand), we proposed a model for CLL pathogenesis due to CD40 ligation within the tumor. To evaluate this issue, we used freshly isolated CLL B cells to examine constitutive and inducible NF-kappaB activity by electrophoretic mobility shift assay. We consistently observed high levels of nuclear NF-kappaB-binding activity in unstimulated CLL B cells relative to that detected in nonmalignant human B cells. In each case examined, CD40 ligation further augmented NF-kappaB activity and prolonged CLL cell survival in vitro. The principle NF-kappaB proteins in stimulated CLL cells appear to be quite similar to those in nonmalignant human B cells and include p50, p65, and c-Rel. In a CD154-positive case, blocking CD154 engagement by mAb to CD154 resulted in inhibition of NF-kappaB activity in the CLL cells. The addition of anti-CD154 mAb resulted in accelerated CLL cell death to a similar degree as was observed in cells exposed to dexamethasone. These data indicate that CD40 engagement has a profound influence on NF-kappaB activity and survival in CLL B cells, and are consistent with a role for CD154-expressing T and B cells in CLL pathogenesis. The data support the development of novel therapies based on blocking the CD154-CD40 interaction in CLL.

[1]  K. Kliche,et al.  Protease activation is required for glucocorticoid-induced apoptosis in chronic lymphocytic leukemic lymphocytes. , 1997, Blood.

[2]  I. Maclennan,et al.  Mechanism of antigen-driven selection in germinal centres , 1989, Nature.

[3]  J. Banchereau,et al.  Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. , 1991, Science.

[4]  W. Sha.  Regulation of Immune Responses by NF-κB/Rel Transcription Factors , 1998, The Journal of experimental medicine.

[5]  E. Schattner.  CD40 Ligand in CLL Pathogenesis and Therapy , 2000, Leukemia & lymphoma.

[6]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[7]  T. Kipps,et al.  Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. , 1993, Blood.

[8]  I. Berberich,et al.  Cross-linking CD40 on B cells rapidly activates nuclear factor-kappa B. , 1994, Journal of immunology.

[9]  F. Caligaris‐cappio.  B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. , 1996, Blood.

[10]  D. Baltimore,et al.  An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. , 1996, Science.

[11]  J. Banchereau,et al.  The CD40 antigen and its ligand. , 1994, Annual review of immunology.

[12]  C. Y. Wang,et al.  TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. , 1996, Science.

[13]  M. Tallman,et al.  Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. , 1995, Blood.

[14]  T. McKinsey,et al.  Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation , 1995, Molecular and cellular biology.

[15]  S. Lederman,et al.  Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help) , 1992, The Journal of experimental medicine.

[16]  P. Libby,et al.  Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Ledbetter,et al.  Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. , 1990, Blood.

[18]  B. Dörken,et al.  Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. , 1997, The Journal of clinical investigation.

[19]  J. Banchereau,et al.  Functions of CD40 on B cells, dendritic cells and other cells. , 1997, Current opinion in immunology.

[20]  E. Clark,et al.  Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40). , 1987, Journal of immunology.

[21]  M. Karin,et al.  Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. , 1997, The New England journal of medicine.

[22]  R. Gaynor,et al.  HTLV-I Tax Protein Binds to MEKK1 to Stimulate IκB Kinase Activity and NF-κB Activation , 1998, Cell.

[23]  J. Banchereau,et al.  Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. , 1992, Blood.

[24]  M J May,et al.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.

[25]  V. Castronovo,et al.  The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines. , 1994, Biochemical pharmacology.

[26]  T. Kipps,et al.  Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal , 1993, The Journal of experimental medicine.

[27]  T. Maniatis,et al.  Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. , 1995, Genes & development.

[28]  K. Kliche,et al.  Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. , 1998, Blood.

[29]  S. Lederman,et al.  A human CD4- T cell leukemia subclone with contact-dependent helper function. , 1991, Journal of immunology.

[30]  C. Y. Wang,et al.  NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. , 1998, Science.

[31]  David Baltimore,et al.  Multiple nuclear factors interact with the immunoglobulin enhancer sequences , 1986, Cell.

[32]  K. Kliche,et al.  Coexpression of CD40 and CD40 ligand in B‐cell lymphoma cells , 1998, British journal of haematology.

[33]  I. Stamenkovic,et al.  A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[34]  G. Cheng,et al.  NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Hay,et al.  Defective IκBα in Hodgkin cell lines with constitutively active NF-κB , 1998, Oncogene.

[36]  E. Schattner,et al.  Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity. , 1998, Blood.

[37]  D. Liebowitz.  Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. , 1998, The New England journal of medicine.

[38]  Seamus J. Martin,et al.  Suppression of TNF-α-Induced Apoptosis by NF-κB , 1996, Science.